The OPSiP study (short for "Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization") is a randomized controlled trial (RCT) that is recruiting 450 participants in Vancouver, British Columbia.
About this study
Group B streptococcus, commonly known as GBS, is a type of bacteria that up to 30 percent of individuals have in their bodies at the time they give birth. Although this bacteria is usually harmless, a small percent of babies born to individuals with GBS in their system can become very ill from it.
Probiotics are live micro-organisms that, when taken in adequate amounts, may have the ability to improve the health of those that take them.
In this study, we will be looking to find out if taking 3 study-specific probiotics daily in pregnancy — taken from 25 weeks gestation — has the ability to lessen the chance of being colonized with GBS. Half of the participants will be randomized to take the probiotics and half will be randomized to take a placebo.
Participant Recruitment began in December 2019.
Clinical trials provide the information needed to find new ways of preventing, detecting, and/or treating diseases. Without participants, there would be no clinical trials. The OPSiP study will be looking to see if probiotics can prevent GBS colonization and your participation will help us to find this out.
If effective, then your help will have paved the way for further research in this area which may then end up being beneficial for future pregnant individuals and their babies. For more on participating go to "About OPSiP."
We are sincerely grateful to the Alva Foundation for their generosity and leadership in the support of early childhood development and helping to improve the health of children.